Learning Objectives

• Identify the etiology and pathophysiology of atherothrombosis
• Recognize the link between inflammation and thrombotic illnesses
• Explain new tools for stroke prevention and prediction in atrial fibrillation
• Identify the optimal duration of anticoagulation for PE and DVT
• Provide advanced therapies such as thrombolysis, catheter-directed therapy, and surgical embolectomy
• Explain the connection between diabetes, metabolic syndrome, and major adverse cardiac events
• Provide patients with useful insights into how a heart-healthy diet can help prevent thrombosis
• Manage a high-risk pregnancy

Intended Audience

This educational activity is designed for physicians, nurse practitioners (NPs), and physician assistants (PAs) interested in changes and advances impacting the care of patients with or at risk for thrombotic disorders.

Topics and Speakers

• Novel Targets For Atherosclerosis Prevention

  • What’s New with TG and AngPTL3 – Aruna D. Pradhan, MD, MPH, MSc
  • What’s New with Lp(a) – Samia Mora, MD
  • What’s New with LDL and ApoB – Jorge Plutzky, MD
  • What’s New with Inflammatory Targets – Paul M. Ridker, MD, MPH

• Peripheral Arterial Disease

  • PAD Pathways for Optimizing Cardiovascular and Limb Outcomes – Marc P. Bonaca, MD, MPH

• Heart Failure

  • Heart Failure and Venous Thromboembolism – Samuel Z. Goldhaber, MD
  • More Than Just Diabetes and Heart Failure SGLT2 – Deepak L. Bhatt, MD, MPH
  • More Than Just Diabetes and Heart Failure GLP1 – Brendan M. Everett, MD, MPH
  • Heart Failure Reduced Ejection Fraction – Marc A. Pfeffer, MD, PhD

• Atrial Fibrillation & Coronary Disease

  • Dual Antiplatelet Therapy and Anticoagulation – Michelle L. O’Donoghue, MD, MPH
  • How to Manage the Anticoagulation Around Ablation and Cardioversions and Watchmans for AF – Bruce A. Koplan, MD

• Anticoagulation

  • Dose-Reduced Direct Oral Anticoagulants Efficacy and Safety – Behnood Bikdeli, MD, MS
  • Duration of Anticoagulation Arterial Thrombosis Navigating Limitations in Data and Variations in Practice – Teresa Carman, MD, RPVI, MS
  • Duration of Anticoagulation Venous Thrombosis – Gregory Piazza, MD, MS
  • Novel Anticoagulation Targets Factor XI and XII Inhibitors – Jeffrey I. Weitz, MD

• Racial Disparities In Arterial And Venous Thrombosis

  • Racial Disparities in Healthcare – Cassandra M. Pierre, MD, MSc
  • Racial Disparities in Arterial and Venous Thrombosis – Karlyn A. Martin, MD

• Genetics

  • VTE Prediction Using Genetics as a Powerful Tool – Nicholas A. Marston, MD, MPH
  • Clonal Hematopoiesis of Indeterminate Potential (CHIP) Association with VTE & PAD – Peter Libby, MD

• COVID And Thrombosis

  • COVID and Thrombosis Mechanisms and Epidemiology – Gregory Piazza, MD, MS
  • Prevention of VTE in COVID-19 Patients – Behnood Bikdeli, MD, MS

• VTE Prevention

  • VTE Prophylaxis for Orthopedic Surgery – Samuel Z. Goldhaber, MD

• PE Reperfusion

  • Device Therapy for PE Reperfusion Navigating a Rapidly Changing Landscape – Gregory Piazza, MD, MS
  • Systemic Fibrinolysis (PEITHO-3) – Samuel Z. Goldhaber, MD

• Pulmonary Hypertension and Thrombosis

  • Chronic Thromboembolic Pulmonary Hypertension – Bradley A. Maron, MD
  • Pulmonary Hypertension After PE That is Not Chronic Thromboembolic Pulmonary Hypertension – Jane A. Leopold, MD, FACC, FAHA, FSCAI

• Post-Thrombotic Syndrome

  • Post-thrombotic Syndrome Epidemiology and Medical Therapy – Susan R. Kahn, MD, MSc, FRCPC, ABIM
  • Intervention, Acute Intervention, and Chronic Venous Obstructive Disease – Suresh Vedantham, MD

• VTE and Cancer

  • Vascular Cardio-Oncology – Javid Moslehi, MD
  • Prevention of Thrombotic Complications of Cancer and Cancer Therapy – Simon Mantha, MD, MPH
  • Treatment of Cancer-Associated Thrombosis – Michael B. Streiff, MD

Date

Date of Original Release: December 31, 2022

Date Credits Expire: December 31, 2025